Mesothelioma Treatment Alerts
A recent study has concluded that Fibulin-3 meets the necessary criteria to be considered a robust blood and effusion biomarker for pleural mesothelioma.
Clinical Trial - Phase II Study of IMC-A12 in Patients Diagnosed with Mesothelioma Who Were Previously Treated With Chemotherapy
The National Cancer Institute is currently recruiting participants to participate in a clinical trial to evaluate IMC-A12 in mesothelioma patients.
A clinical trial to study the effects of Everolimus in patients with malignant pleural mesothelioma is currently underway.
In an article posted in this column a few weeks ago, it was reported that researchers at Madison-based Quintessence Bioscience were waiting for the results of a Phase IIIb clinical trial from Alfacell Corp., a significant East Coast competitor, on an anti-cancer therapeutic compound, Onconase. QBI-139, Quintessence's lead drug candidate, is very similar to Onconase but has not yet gone through clinical testing.
An unusual clinical feature of mesothelioma is the presentation of contralateral mediastinal shift due to pleural mesothelioma tissue, rather than a pleural effusion.
Dr. Paul Sugarbaker, renowned oncologic surgeon specializing in mesothelioma at the Washington Cancer Institute, developed a leading-edge surgical procedure to treat mesothelioma called heated intraoperative intraperitoneal chemotherapy.
Researchers have reported that combination resection, intraperitoneal chemotherapy, and whole abdominal radiation therapy is effective for treating malignant peritoneal mesothelioma.
Radical Decortication/Pleurectomy is the Best Surgical Approach for N2 Malignant Mesothelioma: Presented at recent STS
Stage 3 pure epithelial mesothelioma patients who underwent the more extensive treatment of radical decortication/pleurectomy appear to have significantly better results than patients who had less extensive operations.
Alfacell Corp. said that according to the research findings published in National Academy of Sciences Journal, the company's anti-cancer drug Onconase might be one of the most effective methods of treatment for mesothelioma and lung cancer caused by asbestos.
The first and only drug regimen proven to help patients with an asbestos cancer live longer was approved today by the U.S. Food and Drug Administration.
OSI Pharmaceuticals Inc. is more confident than ever of the potential of its experimental cancer drug Tarceva (erlotinib HCl), even after the failure of a similar drug in a major clinical study this summer, OSI Chairman and CEO Dr. Colin Goddard told investors at the UBS Warburg Global Life Sciences conference here on Wednesday.
New England Journal of Medicine
Cancer Consultants, ID
Health Behavior News Service
Eli Lilly and Company